The iPledge program is a risk management distribution program aimed at preventing fetal exposure to isotretinoin, a potent teratogenic medication primarily used for severe acne. Implemented by the U.S. Food and Drug Administration (FDA), the program ensures that patients, prescribers, and pharmacists adhere to stringent guidelines to minimize the risk of birth defects.
